Cargando…
Syntheses of 25-Adamantyl-25-alkyl-2-methylidene-1α,25-dihydroxyvitamin D(3) Derivatives with Structure–Function Studies of Antagonistic and Agonistic Active Vitamin D Analogs
The active form of vitamin D(3), 1α,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], is a major regulator of calcium homeostasis through activation of the vitamin D receptor (VDR). We have previously synthesized vitamin D derivatives with large adamantane (AD) rings at position 24, 25, or 26 of the side...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377034/ https://www.ncbi.nlm.nih.gov/pubmed/37509118 http://dx.doi.org/10.3390/biom13071082 |
_version_ | 1785079416622153728 |
---|---|
author | Maekawa, Kazuki Ishizawa, Michiyasu Ikawa, Takashi Sajiki, Hironao Matsumoto, Taro Tokiwa, Hiroaki Makishima, Makoto Yamada, Sachiko |
author_facet | Maekawa, Kazuki Ishizawa, Michiyasu Ikawa, Takashi Sajiki, Hironao Matsumoto, Taro Tokiwa, Hiroaki Makishima, Makoto Yamada, Sachiko |
author_sort | Maekawa, Kazuki |
collection | PubMed |
description | The active form of vitamin D(3), 1α,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], is a major regulator of calcium homeostasis through activation of the vitamin D receptor (VDR). We have previously synthesized vitamin D derivatives with large adamantane (AD) rings at position 24, 25, or 26 of the side chain to study VDR agonist and/or antagonist properties. One of them—ADTK1, with an AD ring and 23,24-triple bond—shows a high VDR affinity and cell-selective VDR activity. In this study, we synthesized novel vitamin D derivatives (ADKM1-6) with an alkyl group substituted at position 25 of ADTK1 to develop more cell-selective VDR ligands. ADKM2, ADKM4, and ADKM6 had VDR transcriptional activity comparable to 1,25(OH)(2)D(3) and ADTK1, although their VDR affinities were weaker. Interestingly, ADKM2 has selective VDR activity in kidney- and skin-derived cells—a unique phenotype that differs from ADTK1. Furthermore, ADKM2, ADKM4, and ADKM6 induced osteoblast differentiation in human dedifferentiated fat cells more effectively than ADTK1. The development of vitamin D derivatives with bulky modifications such as AD at position 24, 25, or 26 of the side chain is useful for increased stability and tissue selectivity in VDR-targeting therapy. |
format | Online Article Text |
id | pubmed-10377034 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103770342023-07-29 Syntheses of 25-Adamantyl-25-alkyl-2-methylidene-1α,25-dihydroxyvitamin D(3) Derivatives with Structure–Function Studies of Antagonistic and Agonistic Active Vitamin D Analogs Maekawa, Kazuki Ishizawa, Michiyasu Ikawa, Takashi Sajiki, Hironao Matsumoto, Taro Tokiwa, Hiroaki Makishima, Makoto Yamada, Sachiko Biomolecules Article The active form of vitamin D(3), 1α,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], is a major regulator of calcium homeostasis through activation of the vitamin D receptor (VDR). We have previously synthesized vitamin D derivatives with large adamantane (AD) rings at position 24, 25, or 26 of the side chain to study VDR agonist and/or antagonist properties. One of them—ADTK1, with an AD ring and 23,24-triple bond—shows a high VDR affinity and cell-selective VDR activity. In this study, we synthesized novel vitamin D derivatives (ADKM1-6) with an alkyl group substituted at position 25 of ADTK1 to develop more cell-selective VDR ligands. ADKM2, ADKM4, and ADKM6 had VDR transcriptional activity comparable to 1,25(OH)(2)D(3) and ADTK1, although their VDR affinities were weaker. Interestingly, ADKM2 has selective VDR activity in kidney- and skin-derived cells—a unique phenotype that differs from ADTK1. Furthermore, ADKM2, ADKM4, and ADKM6 induced osteoblast differentiation in human dedifferentiated fat cells more effectively than ADTK1. The development of vitamin D derivatives with bulky modifications such as AD at position 24, 25, or 26 of the side chain is useful for increased stability and tissue selectivity in VDR-targeting therapy. MDPI 2023-07-06 /pmc/articles/PMC10377034/ /pubmed/37509118 http://dx.doi.org/10.3390/biom13071082 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Maekawa, Kazuki Ishizawa, Michiyasu Ikawa, Takashi Sajiki, Hironao Matsumoto, Taro Tokiwa, Hiroaki Makishima, Makoto Yamada, Sachiko Syntheses of 25-Adamantyl-25-alkyl-2-methylidene-1α,25-dihydroxyvitamin D(3) Derivatives with Structure–Function Studies of Antagonistic and Agonistic Active Vitamin D Analogs |
title | Syntheses of 25-Adamantyl-25-alkyl-2-methylidene-1α,25-dihydroxyvitamin D(3) Derivatives with Structure–Function Studies of Antagonistic and Agonistic Active Vitamin D Analogs |
title_full | Syntheses of 25-Adamantyl-25-alkyl-2-methylidene-1α,25-dihydroxyvitamin D(3) Derivatives with Structure–Function Studies of Antagonistic and Agonistic Active Vitamin D Analogs |
title_fullStr | Syntheses of 25-Adamantyl-25-alkyl-2-methylidene-1α,25-dihydroxyvitamin D(3) Derivatives with Structure–Function Studies of Antagonistic and Agonistic Active Vitamin D Analogs |
title_full_unstemmed | Syntheses of 25-Adamantyl-25-alkyl-2-methylidene-1α,25-dihydroxyvitamin D(3) Derivatives with Structure–Function Studies of Antagonistic and Agonistic Active Vitamin D Analogs |
title_short | Syntheses of 25-Adamantyl-25-alkyl-2-methylidene-1α,25-dihydroxyvitamin D(3) Derivatives with Structure–Function Studies of Antagonistic and Agonistic Active Vitamin D Analogs |
title_sort | syntheses of 25-adamantyl-25-alkyl-2-methylidene-1α,25-dihydroxyvitamin d(3) derivatives with structure–function studies of antagonistic and agonistic active vitamin d analogs |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377034/ https://www.ncbi.nlm.nih.gov/pubmed/37509118 http://dx.doi.org/10.3390/biom13071082 |
work_keys_str_mv | AT maekawakazuki synthesesof25adamantyl25alkyl2methylidene1a25dihydroxyvitamind3derivativeswithstructurefunctionstudiesofantagonisticandagonisticactivevitamindanalogs AT ishizawamichiyasu synthesesof25adamantyl25alkyl2methylidene1a25dihydroxyvitamind3derivativeswithstructurefunctionstudiesofantagonisticandagonisticactivevitamindanalogs AT ikawatakashi synthesesof25adamantyl25alkyl2methylidene1a25dihydroxyvitamind3derivativeswithstructurefunctionstudiesofantagonisticandagonisticactivevitamindanalogs AT sajikihironao synthesesof25adamantyl25alkyl2methylidene1a25dihydroxyvitamind3derivativeswithstructurefunctionstudiesofantagonisticandagonisticactivevitamindanalogs AT matsumototaro synthesesof25adamantyl25alkyl2methylidene1a25dihydroxyvitamind3derivativeswithstructurefunctionstudiesofantagonisticandagonisticactivevitamindanalogs AT tokiwahiroaki synthesesof25adamantyl25alkyl2methylidene1a25dihydroxyvitamind3derivativeswithstructurefunctionstudiesofantagonisticandagonisticactivevitamindanalogs AT makishimamakoto synthesesof25adamantyl25alkyl2methylidene1a25dihydroxyvitamind3derivativeswithstructurefunctionstudiesofantagonisticandagonisticactivevitamindanalogs AT yamadasachiko synthesesof25adamantyl25alkyl2methylidene1a25dihydroxyvitamind3derivativeswithstructurefunctionstudiesofantagonisticandagonisticactivevitamindanalogs |